The Maharashtra Food and Drug Administration (FDA) has confirmed that the controversial ‘Coldrif’ cough syrup, recently banned in Tamil Nadu following child fatalities, did not enter the Maharashtra market. The clarification, issued on October 5, 2025, comes amid growing public concern over the spread of unsafe pharmaceutical products across state borders. Maha FDA officials stated that after an extensive inspection of wholesalers, distributors, and pharmacies, no consignments of the product were found within the state. The department also directed local drug inspectors to remain alert and monitor for any unauthorized shipments that might attempt to bypass state-level restrictions. The confirmation aims to reassure consumers and prevent panic, particularly among parents concerned about children’s safety. The agency further announced plans to tighten surveillance and improve inter-state coordination with health departments to prevent the circulation of potentially hazardous drugs. Meanwhile, public health experts have called for a nationwide review of pediatric medicines and over-the-counter formulations, emphasizing stricter quality control to ensure that such incidents do not recur. #MaharashtraFDA #ColdrifCoughSyrup #DrugSafety #PublicHealth #ChildSafety #PharmaRegulation #HealthNews #MedicalSafety #QualityControl #IndiaHealth
The Tamil Nadu government has ordered an immediate ban on the sale and distribution of the popular ‘Coldrif’ cough syrup after reports linked its consumption to the deaths of several children in the state. The directive was issued on October 4, 2025, following investigations by state health authorities and the Food Safety and Drugs Administration (FDA). Preliminary reports suggest that the syrup may have contained contaminants or incorrect formulations, prompting urgent public health action. Hospitals in affected districts confirmed multiple cases of adverse reactions in children, leading to fatalities. Authorities have urged parents to immediately discontinue the use of the syrup and report any symptoms such as nausea, difficulty breathing, or convulsions to medical facilities. The FDA has launched a broader investigation into the manufacturer and is coordinating with central health agencies to ensure accountability and prevent further incidents. Meanwhile, hospitals and health departments are distributing alternative, safe medications and providing guidance to pediatricians and caregivers across Tamil Nadu. The state government has also called for a review of over-the-counter drug monitoring and quality assurance to prevent similar tragedies in the future. #TamilNadu #ColdrifBan #ChildSafety #DrugSafety #PediatricHealth #FDAIndia #PublicHealthAlert #MedicalSafety #HealthAuthorities #SafeMedication
